In the REGENERATE phase 3 trial (NCT02548351) [122], the histological effects and liver-related clinical outcomes of OCA on noncirrhotic biopsy-proven NASH patients with F2–3 or F1 with obesity, T2DM or ALT >1.5× the upper limit of normal. This evidence concerns the gene GPT and type 2 diabetes mellitus.